Addressing the management of atrial fibrillation - A systematic review of the role of dronedarone

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 465-478

  Podda, Gian Marco ^a   Casazza, Giovanni ^b   Casella, Francesco ^b   Dipaola, Franca ^c   Scannella, Emanuela ^b   Tagliabue, Ludovica ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c PARKINSON INSTITUTE   (Italy)

Author keywords

Amiodarone; Arrhythmia; Cardiovascular events

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO;

ADULT; AGED; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; EXTERNAL VALIDITY; FEMALE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PROARRHYTHMIA; HOSPITALIZATION; HUMAN; INTERNAL VALIDITY; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC DYSFUNCTION; THYROID DISEASE;

EID: 84867691109     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S16674     Document Type: Review

References (32)

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272.
2. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57(2):223-242.
3. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.
4. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
6. Ruigomez A, Johansson S, Wallander MA, Rodriguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002;55(4):358-363.
7. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-484.
8. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-364.
9. Cordina J, Mead G. Pharmacological cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev. 2005(2):CD003713.
10. De Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165(3):258-262.
11. Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J. 2005;26(19):2000-2006.
12. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007(4): CD005049.
13. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42(1):20-29.
14. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007; 356(9):935-941.
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
16. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology, A Basic Science for Clinical Medicine. 2nd ed. Boston: Little, Brown; 1991.
17. Higgins JPT, Altman DG, Sterne, JAC, editors. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
18. Guyatt GH, Oxman AD, Kunz R, et al; for the GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol. 2011;64(12):1303-1310.
19. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1(1):e9.
20. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481-1487.
21. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357(10):987-999.
22. Hohnloser SH, Crijns HJ, van Eickels M, et al; for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-678.
23. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605.
24. Davy JM, Herold M, Hoglund C; et al for the ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(3):527. e521-e529.
25. Connolly SJ, Camm AJ, Halperin JL; et al for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-2276.
26. Kober L, Torp-Pedersen C, McMurray JJ; et al for the Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-2687.
27. Pugliano M, Costantino G, Podda GM; for the ATHENA Investigators. Dronedarone in atrial fibrillation. N Engl J Med. 2009;360(23): 2479-2480; author reply 2480-2471.
28. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54(12):1089-1095.
29. http://www.fda.com [homepage on the Internet] United States Food and Drug Administration. FDA Drug Safety Communication January 20, 2011. Severe liver injury associated with the use of dronedarone (marketed as Multaq). Available from: http://www.fda.gov/Drugs/ DrugSafety/ucm240011.htm. Accessed March 28, 2012.
30. Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med. 2010;170(1):27-40.
31. Mendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN. Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med. 2011;171(6):577-584.
32. The Appraisal of Guidelines for Research and Evaluation instrument. Available for download from: http://www.agreetrust.org. Accessed March 29, 2012.